Dermatology Times' Weekly Crossword: June 22, 2025

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

4. This light-based therapy was combined with ritlecitinib to accelerate repigmentation in nonsegmental vitiligo.

8. Nearly half of patients with this autoimmune hair loss disorder responded to ritlecitinib.

9. Peter Lio, MD, emphasized the importance of safety and precision medicine in pediatric management of this condition.

10. Patients with the generalized pustular form of this disease may face up to 5 times higher mortality risk.

12. This cytokine is a therapeutic target for psoriasis and is blocked by several biologics.

13. The INTEGUMENT trial studied atopic dermatitis treatment in this age group using roflumilast 0.05% cream.

14. This type of language in dermatology may improve outcomes for LGBTQ+ patients, especially those with acne.

15. This JAK inhibitor was discussed at RAD 2025 for its role in pediatric atopic dermatitis.

16. The Clean Slate Program at UCSD offers free laser removal of this form of body art to support social reintegration.

Down

1. This JAK1 inhibitor has shown long-term remission in treatment-resistant bullous pemphigoid.

2. This oral JAK3/TEC family inhibitor is used for vitiligo and alopecia areata with sustained results in some patients.

3. This PDE4 inhibitor shows promise as a steroid-free treatment for infant atopic dermatitis.

5. The VALIANT survey highlighted high rates of depression in patients with this pigmentary disorder.

6. (Abbreviation) A German study explored the emotional burden of this occupational eczema affecting the hands.

7. This mental health condition was reported at high rates in individuals living with vitiligo.

11. This AI-powered tool helps visualize potential outcomes of skin care treatments using real patient images.

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.

Answers from our June 15, 2025 puzzle: [Across: 8 - anxiety; 9- EULAR; 10 - Almirall; 12 - hyperpigmentation; 15 - barzolvolimab; 17 - HS; Down: 1 - urticaria; 2 - abrocitinib; 3 - GuaSha; 4 - ALY301; 5 - nemolizumab; 6 - guselkumab; 7 - PEP9; 11 - GPP; 13 - exosomes; 14 - AD; 16 - minoxodil]